Assessment of Inflammatory mediator release, microvascular resistance, and plaque morphology after percutaneous coronary intervention in patients treated with colchicine.

The Heart Research Institute0 个研究点目标入组 25 人开始时间: 2019年10月18日最近更新: 2021年6月7日

适应症

试验速览

暂无简介。

•Inclusion Criteria: Patients (>21yrs) with a clinical need for cardiac catheterisation at Royal
•Prince Alfred Hospital will be invited to participate in the study.

•Patients with greater than 50% stenosis in the left main coronary artery, cardiogenic shock or haemodynamic instability will be excluded from the study. Other exclusion criteria include age <21, pregnancy, those unable to make their own decisions, patients with moderate renal dysfunction (creatinine clearance <50 ml/min) or hepatic dysfunction (ALT [1.5 x upper limit of normal range); thrombocytopenia or leukopenia; pregnant or lactating women and women at risk of pregnancy. Patients already taking colchicine, those with evidence of active infection or inflammatory conditions that might be associated with markedly elevated hs-CRP levels in the blood (e.g., active rheumatoid arthritis) and those taking other anti-inflammatory therapies (e.g. corticosteroids) or strong CYP3A4 inhibitors will also be excluded.

发起方

The Heart Research Institute